6533b7d9fe1ef96bd126bfdf
RESEARCH PRODUCT
Pediatric non-red cell blood product transfusion practices: what's the evidence to guide transfusion of the ‘yellow’ blood products?
Andrea U. SteinbickerEva WittenmeierSusan M. Goobiesubject
medicine.medical_specialtyRed Cellbusiness.industryMEDLINE030204 cardiovascular system & hematologyFibrinogenBlood cell03 medical and health sciences0302 clinical medicineAnesthesiology and Pain Medicinemedicine.anatomical_structureBlood productCryoprecipitatemedicinePlatelet030212 general & internal medicineFresh frozen plasmaIntensive care medicinebusinessmedicine.drugdescription
Purpose of review Research studies pertaining to the management of pediatric non-red cell blood product transfusion is limited. Clinical practices vary within disciplines and regions. Anesthesiologists need evidence-based guidelines to make appropriate and safe decisions regarding transfusion of the 'yellow' blood products for pediatric patients. Recent findings This review outlines clinical indications for transfusion of fresh frozen plasma, cryoprecipitate, platelets, and fibrinogen concentrate in pediatrics. Recent studies of non-red blood cell transfusions in critical, but stable situations are highlighted. Recommendations to guide transfusion of the 'yellow' blood products in operative and non-operative settings are summarized. Special attention is drawn to guidelines in massive hemorrhage and trauma situations. Summary Evidence-based guidelines and expert consensus recommendations exist to guide the transfusion of pediatric non-red blood products and should be followed when transfusing the 'yellow' blood components. As high-quality studies in neonates, infants and children are limited, future research should broaden our knowledge in this direction with the goal to use restrictive strategies to improve patient outcomes.
year | journal | country | edition | language |
---|---|---|---|---|
2020-04-01 | Current Opinion in Anaesthesiology |